Oramed Pharm (ORMP) AI Stock Analysis

• Market Cap: $110.71M
• Dividend Yield: N/A
• Average Volume (3M): 96.35K
• Price to Earnings (P/E): 21.1
• Beta (1Y): 0.60
• Revenue Growth: N/A
• EPS Growth: -217.26%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 41,003,600
• 10 Day Avg. Volume: 90,823
• 30 Day Avg. Volume: 96,349
• PEG Ratio: 0.01
• Price to Book (P/B): 0.68
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.72
• Enterprise Value/Market Cap: -0.21
• Enterprise Value/Revenue: -11.79
• Enterprise Value/Gross Profit: 491.36
• Enterprise Value/Ebitda: 5.76
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Oramed Pharm's overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.

Positive Factors

Strong Balance Sheet

A strong balance sheet with a high equity ratio indicates financial stability, providing a solid foundation for future growth and resilience against financial challenges.

Innovative Business Model

Oramed's focus on oral drug delivery solutions for injectable treatments positions it uniquely in the biotech sector, potentially revolutionizing treatment methods and expanding market opportunities.

Partnership Revenue Model

The company's revenue model, based on partnerships and licensing, allows for diversified income streams and shared risk, enhancing long-term financial sustainability.

Negative Factors

Zero Revenue

The absence of revenue highlights operational challenges and dependency on successful product commercialization, posing risks to financial health and growth prospects.

Negative Cash Flow

Negative cash flows suggest difficulties in sustaining operations without external funding, potentially limiting the company's ability to invest in growth and innovation.

Weak Income Statement

A weak income statement with negative EBIT and unstable net income reflects operational inefficiencies, challenging the company's ability to achieve profitability and long-term success.

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage pharmaceutical company focused on the development of innovative oral drug delivery solutions. The company operates primarily in the biotechnology sector, aiming to transform injectable treatments into oral alternatives. Its flagship product is an oral insulin capsule for the treatment of diabetes, which is designed to improve the quality of life for millions of diabetic patients worldwide.

How the Company Makes Money

Oramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.

Oramed Pharm Financial Statement Overview

Summary

Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.

Income Statement

Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.00M	0.00	1.34M	2.70M	2.70M	2.71M
Gross Profit	-48.00K	-193.00K	1.34M	2.70M	2.70M	2.62M
EBITDA	-4.09M	-14.87M	-15.57M	-36.98M	-25.04M	-11.31M
Net Income	-24.16M	-19.10M	5.53M	-37.76M	-22.24M	-11.51M
Balance Sheet
Total Assets	161.68M	155.28M	220.55M	161.64M	128.00M	44.63M
Cash, Cash Equivalents and Short-Term Investments	97.94M	141.93M	162.05M	155.72M	94.14M	39.90M
Total Debt	912.00K	372.00K	51.62M	894.00K	533.00K	75.00K
Total Liabilities	8.10M	9.93M	57.66M	10.49M	11.48M	11.75M
Stockholders Equity	154.53M	146.26M	163.82M	151.81M	115.77M	32.88M
Cash Flow
Free Cash Flow	-16.09M	-8.43M	-10.55M	-28.41M	-21.56M	-12.52M
Operating Cash Flow	-16.07M	-8.41M	-10.29M	-27.92M	-21.18M	-12.44M
Investing Cash Flow	-50.07M	105.82M	-73.04M	30.21M	-23.76M	4.63M
Financing Cash Flow	-2.86M	-52.04M	51.98M	10.78M	102.89M	23.79M

Oramed Pharm Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.64
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.64 is above the 20-day moving average (MA) of 2.38, above the 50-day MA of 2.23, and above the 200-day MA of 2.25, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 66.58 is Neutral, neither overbought nor oversold. The STOCH value of 80.17 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.

Oramed Pharm Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LGND	67 Neutral	$3.39B	-44.32	-0.49%	―	40.54%	-264.26%
MNKD	63 Neutral	$1.65B	49.13	-59.59%	―	21.48%	162.30%
AMRN	51 Neutral	$333.98M	-3.26	-16.90%	―	-16.92%	-207.34%
ORMP	47 Neutral	$110.71M	21.10	-14.57%	―	―	-217.26%
VSTM	44 Neutral	$531.75M	-2.52	―	―	-78.63%	1.88%
RDHL	41 Neutral	$7.79M	―	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%